Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors

• Published in: Brain research Vol. 1706; pp. 41 - 47
• Main Authors: Buzás, András, Bokor, Péter, Balangó, Beáta, Pintér, Dávid, Palotai, Miklós, Simon, Balázs, Csabafi, Krisztina, Telegdy, Gyula, Szabó, Gyula, Bagosi, Zsolt
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2019
• Subjects: Animals; Corpus Striatum - metabolism; Corticotropin-Releasing Hormone - pharmacology; CRF receptor; Dopamine - metabolism; Dopaminergic Neurons - metabolism; Locomotion - physiology; Locomotor activity; Male; Motor Activity; Nicotine; Nicotine - metabolism; Peptide Fragments - pharmacology; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone - metabolism; Striatal dopamine release; Substance Withdrawal Syndrome - metabolism; Rats; CRF receptor; Locomotor activity; Striatal dopamine release; Nicotine
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/j.brainres.2018.10.028

•Male Wistar were exposed to repeated ip injection with nicotine for 7 days.•On the 8th and the 9th day rats were injected icv with antalarmin or astressin2B.•Horizontal and vertical locomotor activities changed on the 8th and the 9th day.•Dorsal and ventral striatal dopamine releases changed on the 8th and the 9th day.•All the changes observed were attenuated by antalarmin, but not astressin2B. The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.